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Abstract 
Background 
Fear and anxiety based problems are common in dogs. Alongside behaviour modification 
programmes, a range of psychopharmacological agents may be recommended to treat such 
problems, but few are licensed for use in dogs and the onset of action of some can be delayed. The 
low affinity partial benzodiazepine receptor agonist imepitoin (Pexion™, Boehringer Ingelheim) is 
licensed for treating canine epilepsy, has a fast onset of action in dogs and has demonstrated 
anxiolytic properties in rodent models. This case series reports on the use of imepitoin in a group of 
dogs identified as having fear/anxiety based problems. Twenty dogs were enrolled into the study, 
attended a behaviour consultation and underwent routine laboratory evaluation. Nineteen dogs 
proceeded to be treated with imepitoin orally twice daily (starting dose approximately 10 mg/kg, 
with alterations  
as required to a maximum 30 mg/kg) alongside a patient-specific behaviour modification plan for a 
period of  
11–19 weeks. Progress was monitored via owner report through daily diary entries and telephone 
follow-up every two weeks. A Positive and Negative Activation Scale (PANAS) of temperament was 
also completed by owners during baseline and at the end of the study. 
Results 
The primary outcome measure was average weekly global scores (AWG) from the owner diaries. 
Average weekly reaction scores (AWR) for each type of eliciting context was used as a secondary 
outcome. Seventeen dogs completed the trial. Treatment with imepitoin alongside a behaviour 
modification programme resulted in owner reported improvement with reduced AWG and reduced 
AWR for anxiety across a range of social and non-social eliciting contexts including noise sensitivities. 
Significant improvement was apparent within the first week of treatment, and further 
improvements seen at the 11 week review point. There was a significant reduction in negative 
activation (PANAS) with 76.5% of owners opting to continue imepitoin at their own expense after 
completion of the study. 
Conclusions 
This study provides initial evidence indicating the potential value of imepitoin (Pexion™) alongside 
appropriate behaviour modification for the rapid alleviation of signs of fear and anxiety in dogs. 
Further research with a larger subject population and a placebo control would be useful to confirm 
the apparent efficacy reported here. 
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Background 
Fear and anxiety-related problems in dogs are common. In the People’s Dispensary for Sick Animals 
Pet Animal Welfare report [1] (2011) 82% of owners reported their dog was afraid of ‘something’. 
Another study [2] found that 25% of owners considered their dogs to be fearful of noises, but 49% 
reported at least one behavioural sign suggestive of fear when exposed to loud noises. The  
Association of Pet Behaviour Counsellors in the UK [3] report that 8% of canine cases were referred 
for a  
specific fear or phobia, 6% for owner-absent problems (which includes “separation anxiety”) and 
64% for aggressive behaviour towards people and dogs (the extent to which fear or anxiety played a 
role in these cases was not stated). In the US, a study [4] found 10.3% of cases had a specific fear, 
anxiety or phobia, 14% separation anxiety and 22% fear-related aggression towards people. 
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Both fear and anxiety can occur in the context of the perception of increased threat to the individual 
[5]. Whereas fear occurs in response to the presence of a specific aversive trigger, anxiety develops 
when an animal anticipates a negative outcome such as in a location where they previously 
encountered an aversive trigger [67]. In a novel or unpredictable environment, or in a situation of 
ambiguous threat, a dog may experience anxiety and uncertainty due to a conflict of approach and 
avoidance tendencies [8]. Dogs may also experience anxiety associated with the departure of the 
owners. These may arise from fear and anxiety related associations (e.g. fear of isolation, fear of 
stimuli occurring in the context of being separated) as well as problems related to separation from 
an attachment figure (PANIC sensu Panksepp, [9]). Different neurochemical networks are thought to 
underpin these different forms of anxiety [1011]. A further distinction may also be made between 
social and non-social stimuli that trigger a response [12]. 
The affective state of fear and anxiety can operate at the level of: a specific emotional reaction (i.e. 
in response to a specific aversive trigger); a mood change (longer lasting emotional changes that bias 
behaviour and cognition occurring in response to a series of related aversive events); or as a feature 
of temperament (behavioural predispositions arising from the interaction of genetic and early 
experiential factors). One method developed for assessing aspects of temperament in dogs is the 
Positive and Negative Activation Scale (PANAS) [13], a reliable and valid measure of positive 
activation/affect (mediates behavioural approach and neophilia) and negative activation/affect 
(mediating behavioural  
inhibition, withdrawal and avoidance (fear-anxiety)). Anxious emotional reactions, moods and 
temperament can all be problematic for an owner and are a cause for welfare concern. 
Fear and anxiety related problems in dogs are principally resolved using behaviour modification 
techniques such as desensitisation and counter-conditioning  
(operant and classical) [14]. Various psychopharmacological agents have been suggested as 
potentially useful adjuncts in such cases, [15] including: tri-cyclic antidepressants (TCAs) e.g. 
amitriptyline [16] and clomipramine [1718]; tetra-cyclic antidepressants e.g. mirtazapine [14]; 
selective serotonin reuptake inhibitors (SSRIs) e.g. fluoxetine [1920]; monoamine oxidase inhibitors 
(MAO-Is) e.g. selegiline [21]; progestins e.g. megestrol acetate [22]; anticonvulsants e.g. 
phenobarbital [23]; benzodiazepines e.g. diazepam [24] and  
alprazolam [25]; alpha-2 adrenergic receptor agonists clonidine [26] and dexmedetomidine [27]. 
However, there are few psychopharmacological agents licensed for use in dogs. In the European 
Union (EU), where a licensed drug is not available, veterinary surgeons should follow the 
prescription cascade as outlined in the European Union Veterinary Medicines  
Directive (2001/82) [28]. Although this allows the use of the benzodiazepines listed above because 
they have a  
human licence, the prescription cascade regulations indicate that for a different condition in the 
same species should be given preference. In the United States (US), where a veterinary formulation 
does not exist informed consent can be obtained from a client to use human formulations “extra-
label”. 
At the time of writing, clomipramine (Clomicalm, Novartis – EU and US), selegiline (Selgian, CEVA - 
EU; Anipryl, Zoetis, US), the progestogen megestrol acetate (Ovarid, Virbac – EU), fluoxetine 
(Reconcile – not currently available) and most recently dexmedetomidine (Sileo, Zoetis) all have 
veterinary licenses for dogs. 
The effects of using medications such as SSRIs and TCAs can typically take around 3–5 weeks to 
become apparent [15]. Benzodiazepines have a faster onset of action [1529], but no 
benzodiazepines are licensed in any form for use in dogs in the EU nor available as veterinary 
formulations in the US. 
Benzodiazepines exhibit their effects by binding to a specific benzodiazepine binding site on the 
inhibitory neurotransmitter GABA (ɣ-aminobutyric acid) receptor and they can exhibit anxiolytic 
properties [30]. One retrospective study in dogs explored the anxiolytic properties of diazepam as 
reported by owners, where the response was variable, where 53% of owners discontinued diazepam 
therapy due to lack of efficacy and 58% due to adverse effects [24]. In the same study in the group of 
dogs classed as having ‘thunderstorm phobia’ 100% of owners classed the treatment as effective. 
Dosages of diazepam varied widely in this study, which is important as the effects of 
benzodiazepines are dose dependent with moderate doses often needed for anxiolytic effects and 
higher doses more likely to cause adverse effects such as ataxia [15]. In addition, tolerance can 
develop with the use of benzodiazepines [1531]. However, as benzodiazepines can be highly 
effective there is value in further exploring the safety and reliability of using this class of drugs as 
anxiolytics in dogs. 
Imepitoin (Pexion™, Boehringer Ingelheim) is a low affinity partial benzodiazepine receptor agonist 
[3233] licensed in the EU for the reduction of the frequency of generalised seizures due to idiopathic 
epilepsy in dogs [34]. When used in dogs, imepitoin appears to be well tolerated and safe [3536]. 
Pharmacokinetic studies in dogs show imepitoin has a fast onset of action of around 2–3 h after 
single oral dosing [37]. Fear and anxiety are common behavioural co-morbidities in canine epileptic 
patients [38]. During the development of imepitoin for the treatment of idiopathic epilepsy in dogs, 
it was reported anecdotally that some owners wanted to continue using imepitoin due to reported 
improvements in their dog’s behaviour even when seizure frequency was unaffected [39]. In a 
variety of experimental rodent models, imepitoin has demonstrated anxiolytic properties [394041]. 
In addition, being a low affinity partial agonist, the likelihood of developing reduced efficacy related 
to tolerance and potential for abuse are lower which may offer advantages over full agonist 
benzodiazepines [39]. 
The aim of the current study was to undertake an initial investigation of the potential value of 
imepitoin alongside an individualised behaviour modification programme for the treatment of a 
range of anxiety and fear related behaviour problems in dogs through a carefully monitored case 
series. 
Methods 
Subjects 
Cases were recruited following a local publicity campaign via referral from the owner’s regular 
veterinary surgeon. Clients were offered a free behaviour consultation, blood test, trial medication 
and follow up for a period of up to three months. Potential cases were screened using a series of 
inclusion and exclusion criteria (Table 1). 
Table 1 
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Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
At least 6 months of age 
Greater than 5 kg bodyweight 
Behavioural complaint related to fear-anxiety as 
diagnosed by a  
veterinary behaviourist 
Lactating or pregnant bitch 
Male breeding dog 
Dogs receiving phenobarbital treatment for 
epilepsy 
Any current uncontrolled medical problem 
Table 1 
AQ5 
Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Incidences of behavioural complaint apparent at 
least twice a week 
Willing to attend a behaviour consultation at the 
University of Lincoln 
Willing to commit to giving medication for up to a 
3 month period if  
medication deemed to be of potential benefit to 
the case (owner has  
option of withdrawing from study at any time) 
Willing to have a blood sample taken from their 
dog for routine  
laboratory evaluation (at no expense to owner), 
prior to use of any  
medication 
Willing to complete all study paperwork including 
a daily diary referring  
to the animal’s behaviour problem and more 
global behaviour 
Severely impaired hepatic function 
Severe renal disorders 
Severe cardiovascular disorders 
Significant family related risk factors affecting 
risk to individuals from  
the dog’s behaviour identified (e.g. toddlers in 
the home in the case  
of aggressive behaviour towards people; 
aggression between dogs  
within home) 
To be considered for the study, 4 initial documents had to be completed: a veterinary referral form 
to be completed by their referring vet and returned with a full medical history; the University of 
Lincoln Animal Behaviour Clinic standard client questionnaire; a Positive and Negative Activation 
Scale (PANAS); an individualised diary (Additional file 1) to be completed to provide one week of 
baseline data for their dog’s reaction in eliciting context(s) established through a telephone 
discussion. The diary was adapted from The Lincoln Sound-Sensitivity Scale [10] to relate more 
broadly to recognisable signs of fear and anxiety in contexts other than noises. To do this an on-line 
forum of pet behaviour counsellors [42] was asked to provide signs they would attribute to fear and 
anxiety in dogs. As a result of this three signs were added to the diary – yawning; licking lips; moving 
away. This gave 20 specific signs with an additional ‘others’ category. The ‘frequency’ score was 
replaced by an ‘Event Occurrence’ box which could be marked ‘yes’ or ‘no’. The severity score range 
was changed from ‘0–5’ to ‘1–5’. A total score for the dog’s reaction to that eliciting context on that 
occasion, could then be calculated by totalling each severity score for each sign/category (maximum 
score = 105). Examples of eliciting contexts included: encounters with strangers; noises; dogs etc. 
The same diary format was used during baseline and the follow up period to monitor the dog’s 
reactions (‘Event occurrence’ and ‘Severity’) based on the owner’s observation and scoring. For the 
single dog with separation related problems (Case 17), video footage was taken weekly whilst the 
dog was home alone and reviewed by the owner in order to complete the diary scoring. Of the initial 
28 owners sent this information, 7 failed to return the complete paperwork and one dog was 
euthanized before the consultation for unrelated reasons. This left 20 dogs with suspected fear and 
anxiety related problems. 
The clinician in immediate charge of the case (KM) under the supervision of a European and RCVS 
recognised specialist in behavioural medicine (DM) assessed all the documents completed at the 
enrolment stage. 
Behaviour consultation 
Each of the 20 dogs in the initial group was brought to the University of Lincoln Animal Behaviour 
Clinic for a behaviour consultation, typically lasting 2–3 h. The  
approach used to establish a diagnosis relating to fear-anxiety adopted the systematic and scientific 
evaluation of the four key components of emotion (as described by Mills et al., [10]) relating to 
context, physiological arousal, behavioural tendencies and communicative elements. 
Clinical examination and blood sampling 
During the consultation, a full clinical examination was performed on each dog and bodyweight was 
measured. Jugular venepuncture was performed to obtain a  
complete blood count, serum biochemistry, thyroid panel (fT4, TT4, cTSH) and basal cortisol values 
for each dog. 
Behaviour modification programmes 
Given the wide range of presenting problems, it was not desirable to standardise the treatment 
protocols for each dog. Behaviour modifications were tailored to the individual, taking into account 
the dog, the presenting problems, the owner and other factors relating to the dog’s specific 
environment. Advice was given during the consultation on techniques, which were demonstrated 
where necessary, and owners were provided with an aide memoire of key points, followed up by a 
full written report within 7 days of the consultation. 
Use of imepitoin 
As imepitoin is licensed for use in dogs at a dose range of 10-30 mg/kg twice daily, all cases were 
commenced on a dose around 10 mg/kg twice daily. During the study, and depending on the 
individual’s progress, dose alterations were made. Dose changes were made at intervals of no less 
than two week periods. The rationale for increasing the dose was twofold: 1) if there was no 
apparent improvement at the previous dose; 2) if improvement at the previous dose had plateaued 
and the behaviour problem was not resolved to the satisfaction of the owner and behaviour 
clinicians. 
Monitoring during follow-up period 
During the follow up period, owners completed an eliciting context diary sheet every time their dog 
was exposed to an eliciting context identified in the baseline period, and these were submitted to 
the investigators every two weeks. These diaries were scored and a telephone call to the owner was 
arranged to review progress. 
End of study 
All cases used in the final analysis were followed for at least 3 months including the one week of 
baseline monitoring before reaching the ‘decision point’ (this varied between 11 to 19 weeks 
depending on the availability of the owner to complete a telephone survey at the end of the study). 
At this time owners were asked to complete a second PANAS and questioned about various aspects 
of their experience of using imepitoin including: ease of administration; satisfaction with overall 
treatment success; whether they would use imepitoin at their own expense (and if so, tactically or 
continuously). They were also given the clinician’s opinion on using imepitoin for their dog in the 
future and were offered further advice on behaviour modification as necessary. In those owners 
continuing imepitoin responsibility for prescribing imepitoin was passed to the referring veterinary 
surgeon. Imepitoin can be stopped abruptly, however for those owners stopping imepitoin, 
guidelines were given for weaning which was typically reducing each dose by 50% for 2 weeks before 
stopping completely 
Statistical analysis 
The data were analysed informally for evidence of a relationship between imepitoin dosing and 
owner report of changes in behaviour with statistical analysis undertaken using Minitab 17. 
Normality of distribution of data were assessed using Anderson-Darling normality tests. Effect sizes 
were calculated for all assessments of difference using Cohen’s d [43]. 
Effects on reactions 
Two main metrics were used to monitor efficacy on fear-anxiety reaction scores: average weekly 
fear-anxiety reaction scores (AWR) and average weekly global fear-anxiety scores (AWG). The 
equations were developed specifically for this study to use the owner’s diary entry scores to assess 
response and control for the number of eliciting contexts. 
In addition, given that the eliciting contexts did not occur every week, we adopted a method of 
conservative data imputation in order to avoid having missing scores. Imputations for responses in 
weeks when the eliciting context did not occur in a given week were made using the following rules: 
if a week of data was missing during the follow up, the average of the weeks on either side was 
taken and imputed (i.e. the value used for that week was estimated from the average of the week 
before and afterwards); if in the final week of the follow up period, there was no eliciting context, 
the last value obtained before this was imputed. This method probably provided a conservative 
estimate of the effect, potentially underestimating any effect, since it referred back to an earlier 
stage of treatment. At all the time points analysed (baseline, week 1, week 11 and decision point): 
for the primary measure of interest, average global weekly scores, 3 imputations were made out of 
68 entries (3/68 = 4.4%); for the measure of secondary interest, average weekly reactions, 28 
imputations were made out of 140 entries (28/140 = 20%). All these data related to an absence of 
the eliciting context in a given week (e.g. a week where there was no exposure to an eliciting context 
recorded by the owner) and not lost data from recorded responses. 
Statistical analysis was stratified with AWR and AWG as the primary outcome measures and 
subsequent analyses post hoc based on the significance of the primary measures. As there were 2 
measures a Bonferroni correction was applied to AWR and AWG only as to apply it to all post hoc 
calculations would risk a type II error. 
Average weekly reactions scores 
The average weekly reaction score (AWR) (maximum score 105) was calculated for each dog for each 
eliciting context as shown in the example below for a dog with noise sensitivities: 
AWR (individual noise)=Sum of diary scores for that individual noise that weekNumber of exposures 
to that individual noises that week  AWR (individual noise)=Sum of diary scores for that individual no
ise that weekNumber of exposures to that individual noises that week 
AWR (noises)=Sum of all AWR (individual noises) that weekNumber of different individual noises exp
osed to that week  AWR (noises)=Sum of all AWR (individual noises) that weekNumber of different in
dividual noises exposed to that week 
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Similar equations were used to calculate AWR scores for dogs with social fear-anxiety and also non-
social fear-anxiety. To compare differences in the AWR in dogs between eliciting contexts grouped 
into noise sensitivities, social fear-anxiety and non-social fear-anxiety (excluding noise sensitivities at 
specific time points (week 1, week 11, decision point) whilst on treatment through the study, paired 
sample t-tests were used. The accepted level of significance after Bonferroni correction was 
p < 0.025. 
Average weekly global scores 
The average weekly global score (AWG) (maximum score 105) was calculated for each dog using the 
following equation: 
AWG=Sum of all AWR that weekNumber of eliciting contexts recorded that week  AWG=Sum of all A
WR that weekNumber of eliciting contexts recorded that week 
To compare the average weekly global scores in dogs between baseline and specific time points 
(week 1, week 11, decision point) whilst on treatment through the study, paired sample t-tests were 
used. The accepted level of significance after Bonferroni correction was p < 0.025. 
Effects on temperament 
Positive and negative activation 
To compare the effects of treatment on owner reported positive and negative activation (from the 
PANAS) between baseline and the decision point of treatment, paired sample t-tests were used. A 
value of p < 0.05 was considered significant. 
Owner satisfaction with treatment 
A Spearman’s correlation coefficient was computed to assess whether owner satisfaction with 
treatment success correlated with: i) changes in reactions (percentile reduction in average global 
weekly fear-anxiety reactions from baseline to decision point); ii) changes in temperament 
(percentile reduction in negative activation from baseline to decision point). A value of p < 0.05 was 
considered significant. 
At the end of the study, owners were also asked about their interest in continuing treatment with 
imepitoin at their own expense and to rate the ease of administration of the imepitoin 
Results 
Demographics 
The initial group was composed of 20 dogs (see Table 2): three dogs were withdrawn from the study: 
case 1 due to change in analgesia during the follow-up period whilst on imepitoin case 4 due to a 
reported adverse event whilst on imepitoin; case 18 due to abnormalities in initial laboratory 
evaluation results before imepitoin was commenced. This left 17 dogs in the final analysis (Table 3) 
comprising 11 females (64.7%) and 6 males (35.3%) (all dogs were neutered), of a range of breeds 
and ages ranging from 1 year 1 month to 10 years 7 months (average age of 4 years 6 months). 
Bodyweight ranged from 5.0 kg to 36.7 kg (average bodyweight 18.9 kg). All dogs had been owned 
for a minimum of 3 months by their owners prior to enrolment. 
Table 2 
Initial group and overview of clinical details and withdrawals 
Case 
No. 
Breed Sexa 
Age 
at 
clinic 
visit 
Weight 
(kg) 
Eliciting 
contexts 
recorded 
Other 
treatment
s 
Notes 
on 
other 
treatme
nts 
Adverse 
events 
Reason 
for 
withdra
wal 
1 
Cross-
breed 
MN 
3 y 
8mo 
21.00 
Noises; 
Carrying 
objects; 
Entering  
back door 
Meloxicam 
SID 
Change
d to 
firocoxi
b during  
study 
Y 
Change 
of 
analgesia 
2 
Cross-
breed 
FN 6y 11.60 Noises 
Carprofen 
SID 
Continu
ed 
during 
study 
N N/A 
3 
Cross-
breed 
MN 
3y 
7mo 
21.30 Noises None - N N/A 
4 
Labrador 
Retriever 
FN 7y 23.75 
Noises; 
Visitors; 
Dogs 
None - Y 
Adverse 
events 
5 
Staffordshi
re Bull  
Terrier 
FN 
10y 
7mo 
18.45 Noises 
Meloxicam 
SID 
Trialled 
only, 
not 
used 
during  
study 
N N/A 
6 Whippet FN 
3y 
5mo 
12.74 
Noises; 
Walking 
None - N N/A 
7 
Staffordshi
re Bull  
Terrier 
FN 
2y 
5mo 
18.98 
Noises; 
Walking 
None - Y N/A 
Table 2 
Initial group and overview of clinical details and withdrawals 
Case 
No. 
Breed Sexa 
Age 
at 
clinic 
visit 
Weight 
(kg) 
Eliciting 
contexts 
recorded 
Other 
treatment
s 
Notes 
on 
other 
treatme
nts 
Adverse 
events 
Reason 
for 
withdra
wal 
8 
Brittany 
Spaniel 
FN 
8y 
4mo 
12.78 
Noises; 
Walking 
None - N N/A 
9 
English Bull 
Terrier 
FN 
2y 
8mo 
20.30 
Visitors; 
Strangers; 
Noises; 
Moving  
from sofa 
Firocoxib 
SID 
Trialled 
only, 
not 
used 
during  
study 
N N/A 
10 
Labrador 
Retriever 
MN 
3y 
9mo 
25.75 Noises None - N N/A 
11 
German 
Wire- 
haired 
Pointer 
MN 
4y 
1mo 
31.60 
Novel 
items; 
Strangers; 
Visitors;  
Postal 
delivery; 
Noises 
Meloxicam 
SID 
Trialled 
only, 
not 
used 
during  
study 
Y N/A 
12 
Tervuren 
Belgian 
Shepherd 
MN 
5y 
1mo 
23.40 
Noises; 
Walking 
Carprofen 
SID 
Trialled 
only, 
not 
used 
during  
study 
N N/A 
13 
Cross-
breed 
FN 
4y 
10mo 
20.20 
Noises; 
Visitors 
None - N N/A 
14 
Cross-
breed 
FN 
1y 
1mo 
20.00 
Visitors; 
Strangers; 
Crowded 
areas;  
None - N N/A 
Table 2 
Initial group and overview of clinical details and withdrawals 
Case 
No. 
Breed Sexa 
Age 
at 
clinic 
visit 
Weight 
(kg) 
Eliciting 
contexts 
recorded 
Other 
treatment
s 
Notes 
on 
other 
treatme
nts 
Adverse 
events 
Reason 
for 
withdra
wal 
Dogs; New 
environme
nts 
15 
Jack Russell 
Terrier 
FN 5y 7.36 
Noises; 
Walking 
None - N N/A 
16 
Cross-
breed 
FN 
2y 
3mo 
18.48 Noises None - N N/A 
17 
Cross-
breed 
FN 
2y 
9mo 
5.00 
Home 
alone 
None - Y N/A 
18 
Border 
Collie 
FN 
6y 
7mo 
12.86 Noises 
Firocoxib 
SID 
- N/A 
Blood 
results 
19 
Cross-
breed 
MN 
1y 
7mo 
15.40 
Dogs; 
Strangers; 
Visitors 
None - N N/A 
20 
German 
Shepherd 
MN 
5y 
1mo 
36.70 Noises 
Meloxicam 
SID 
Continu
ed 
during 
study 
Y N/A 
aM male, F female, N neutered, y years, mo months, Y yes, N no, N/A not applicable 
Table 3 
Population used in final analysis, dose of imepitoin, AWG and PANAS at specific time points and 
owner satisfaction 
Ca
se 
No
. 
Baseline Week 1 Week 11 Decision 
Max. 
dose 
of  
imepit
oin  
Score 
Reducti
on  
Negativ
e 
Activati
on  
% 
Score 
Reduct
ion  
Negati
ve 
Owner  
Satisfac
tion 
Continu
ation of  
treatme
nt at 
owner’s  
AW
G 
Dose 
(mg/kg) 
AW
G 
Dose 
(mg/
kg) 
AW
G 
Dose 
(mg/
kg) 
AW
G 
Dose 
(mg/
kg) 
Table 2 
Initial group and overview of clinical details and withdrawals 
Case 
No. 
Breed Sexa 
Age 
at 
clinic 
visit 
Weight 
(kg) 
Eliciting 
contexts 
recorded 
Other 
treatment
s 
Notes 
on 
other 
treatme
nts 
Adverse 
events 
Reason 
for 
withdra
wal 
(mg/k
g BID) 
(Baselin
e to 
Decisio
n) 
Activat
ion  
(Baseli
ne to 
Decisio
n) 
expense 
– Y/N  
(C/T) = b
asis of 
use 
2 
46.
70 
0 
26.
50 
8.6 9.00 30.2 
4.0
0 
30.2 30.2 −0.05 −6.25 S Y (C) 
3 
11.
57 
0 
2.5
0 
9.4 0.50 19.8 
2.5
0 
19.8 19.8 −0.17 −22.67 S Y (T) 
5 
32.
33 
0 
24.
50 
10.8 
11.0
0 
21.6 
0.0
0 
21.6 21.6 −0.38 −47.50 VS Y (C) 
6 
3.3
6 
0 
0.8
8 
11.8 0.00 3.9 
0.0
0 
11.8 11.8 −0.04 −4.76 VS Y (T) 
7 
20.
94 
0 
4.3
6 
10.5 5.00 10.5 
5.0
0 
10.5 10.5 −0.36 −46.15 VS Y (C) 
8 
19.
75 
0 
3.3
3 
11.7 0.59 11.7 
0.0
0 
23.5 23.5 −0.04 −6.25 S Y (T) 
9 
12.
00 
0 
7.3
3 
9.9 3.34 9.9 
6.0
0 
19.8 19.8 −0.18 −30.14 S Y (C or T) 
10 
23.
67 
0 
27.
50 
9.7 6.67 19.3 
6.5
0 
19.3 19.3 −0.16 −22.22 VS Y (T) 
11 
28.
07 
0 
13.
38 
12.7 9.00 19.0 
9.6
7 
19.0 19.0 −0.15 −21.13 S Y (T) 
12 
34.
75 
0 
34.
00 
10.7 9.64 19.2 
17.
58 
29.9 29.9 −0.07 −8.54 PP Y (C) 
Table 2 
Initial group and overview of clinical details and withdrawals 
Case 
No. 
Breed Sexa 
Age 
at 
clinic 
visit 
Weight 
(kg) 
Eliciting 
contexts 
recorded 
Other 
treatment
s 
Notes 
on 
other 
treatme
nts 
Adverse 
events 
Reason 
for 
withdra
wal 
13 
29.
75 
0 
3.5
0 
9.9 
16.6
7 
19.8 
2.5
0 
29.7 29.7 −0.31 −34.07 S Y (C or T) 
14 
28.
58 
0 
12.
78 
10.0 
11.7
5 
20.0 
5.5
0 
20.0 20.0 −0.15 −17.24 PP N 
15 
34.
91 
0 
21.
00 
13.6 8.00 30.5 
1.0
0 
30.5 30.5 −0.07 −8.54 VD N 
16 
7.6
1 
0 
4.5
9 
10.8 7.00 29.8 
7.0
0 
29.8 29.8 0.05 9.80 PP N 
17 
28.
00 
0 
21.
00 
10.0 1.00 5.0 
1.0
0 
5.0 10.0 −0.03 −5.88 VS Y (C) 
19 
28.
89 
0 
19.
84 
9.7 
16.3
3 
9.7 
15.
50 
19.4 19.4 −0.16 −18.18 VS Y (C or T) 
20 
6.3
3 
0 
3.3
3 
10.9 8.00 21.8 
9.5
0 
21.8 21.8 −0.22 −30.14 PP N 
AWG Average weekly global score, Baseline Baseline week, Decision Decision point (11–19 weeks); 
Y yes, N no, VS very satisfied, S satisfied, PP partly satisfied/partly dissatisfied, D dissatisfied, VD 
very dissatisfied,  
C continuous use, T tactical use 
Clinical examination and laboratory evaluation findings 
Clinical examination revealed abnormalities in 6 cases, with some cases having more than 1 
abnormality: gait abnormalities/musculoskeletal problems (5 dogs), interdigital cyst (1 dog), 
entropion (1 dog), dental disease (1 dog). Further investigations/treatments were performed at the 
referring veterinary practices. Where this included the use of trial analgesia, or surgical correction 
(canine extraction, entropion correction) a new baseline week of diary entries was established after 
recovery/once deemed stable on analgesia for approximately 4 weeks. Laboratory evaluation 
revealed abnormalities in one dog (case 18) indicative of atypical hypoadrenocorticism and this dog 
did not proceed to the treatment group. 
Adverse events 
Among the 19 dogs treated with imepitoin, 7 adverse events were reported in 6 dogs, these were 
not necessarily associated with medication but are recorded here in accordance with best practice. 
Two dogs showed signs of ataxia, and 1 dog chewed some plastic and vomited. These three incidents 
resolved without specific treatment whilst continuing the imepitoin. Recurrence of a pre-existing 
lameness occurred in Case 1 resulting in withdrawal from the study by the investigators due to a 
change in analgesia regime by the referring veterinarian. Diarrhoea was seen in 1 dog (Case 17) 
which resolved on cessation of imepitoin at 10 mg/kg; when the drug was reintroduced at the lower 
dose of 5 mg/kg there was no recurrence in diarrhoea and the dog remained on this dose. Case 4 
had 2 episodes of ataxia and muscle tremors, (including around the head) the first during week 7 and 
the second during week 8 of treatment with 10 mg/kg imepitoin. Both of these episodes occurred 
around the time where noises were audible which had historically resulted in a fearful response. The 
blood profile was repeated and no abnormalities were detected. Despite general improvements in 
behaviour in response to noise out with these events, the owner opted to stop the imepitoin and the 
dog was withdrawn from the study. 
Fear-anxiety triggers 
Of the 17 cases used in the final analysis 6 cases (35.3%) had a single eliciting context monitored, 
with the remaining 11 cases (64.7%) having 2 or more eliciting contexts each. This gave a total of 35 
different eliciting contexts for fear-anxiety: 13 social (visitors, strangers, dogs, crowded areas, home 
alone) and 22 non-social (14 of which were noises, the remainder being: walking, moving from sofa, 
novel items, postal delivery, new environments). 
Behaviour modification programmes 
Behaviour modification recommendations generally included managing the dog’s exposure to 
triggers which included environmental modifications and reinforcing appropriate behaviour. Other 
recommendations included introduction of a safe haven at home (12 cases); operant 
counterconditioning protocols with hand-touch to check-in with owner when the dog has heard a 
noise on walks (10 cases); desensitisation and counterconditioning protocols with sound CDs (9 
cases – only 1 of the 9 used the sound CD during the follow up period); basket muzzle training (4 
cases); teaching a ‘go to mat’ behaviour (3 cases); introduction of activity feeders (3 cases); 
introduction of front-attaching harness (2 cases); desensitisation and counterconditioning to vet 
practice (1 case); toilet training advice (1 case); cues for ‘say hello, say goodbye’ when meeting and 
disengaging from other dogs (1 case). The single case of separation related problems was advised on 
desensitisation to leaving rituals, introduction of safety signal when leaving dog alone, changing 
leaving/returning ritual and teaching increased independence from owner. 
Use of imepitoin 
During the study, of the 17 dogs in the final analysis, 4 received a maximum trial dose of around 
30 mg/kg twice daily, 10 dogs received a maximum trial dose of around 20 mg/kg twice daily and 2 
dogs remained on the initial dose of around 10 mg/kg twice daily, with 1 dog dropping down to and 
being maintained on 5 mg/kg twice daily. Mean doses of imepitoin being used at key time points 
were: week 1 (mean = 10.6 mg/kg,  
median = 10.5 mg/kg); week 11 (mean = 17.7 mg/kg,  
median = 19.3 mg/kg); decision point (mean = 21.3 mg/kg, median = 20.0 mg/kg). 
Effects on reactions 
Average weekly global scores 
The primary measure of interest was the average weekly global scores (AWG). An Anderson-Darling 
normality test showed that the data distribution was not significantly different from normal across 
the 17 subjects at baseline (p = 0.306), week 11 (p = 0.463), decision point (p = 0.088) and mean 
(p = 0.064), but were significantly different to normal at week 1 (p = 0.037). In this situation, 
parametric tests can be used to examine effects within the population studied, but generalisation to 
the wider population should be more cautious [44] for the data relating to non-normally distributed 
data. Given the acknowledged preliminary nature of this study (case series), it is therefore 
acceptable to use parametric tests with this caution acknowledged. Summary effects are displayed 
in Table 4. 
Table 4 
Average weekly global fear-anxiety reaction scores for all 17 dogs in final analysis 
Week 
Average weekly global fear-anxiety reaction score 
t-value 
(16) 
p-
value 
dCohen 
Mean +/− SD 
Decrease from baseline 
(95% CI) 
Median (range) 
Baseline 
23.37 +/− 
11.87 
- 
28.00 (3.36–
46.70) 
- - - 
1 
13.55 +/− 
10.75 
9.82 (5.76,13.88) 
12.78 (0.88–
34.00) 
5.13 <0.001 −0.867 
11 7.26 +/− 5.13 16.10 (10.88,21.32) 8.00 (0–16.67) 6.54 <0.001 −1.762 
Decision 5.49 +/− 5.21 17.88 (11.48,24.28) 5.00 (0–17.58) 5.92 <0.001 −1.951 
There was a statistically significant difference in the AWG between baseline and all specific time 
points whilst on treatment. These effect sizes are large and the results indicate that imepitoin 
alongside a behaviour modification programme had a useful effect on reducing AWG in dogs, with 
an initial meaningful effect being seen within the first week of treatment. 
Average weekly reaction scores 
The secondary measure of interest was the average weekly reaction scores (AWR) between the 
eliciting context groups previously described. An Anderson-Darling normality test showed that the 
data were normally distributed across the average weekly reactions for different eliciting contexts 
and subjects at baseline (p = 0.565), week 1 (p = 0.051) and week 11 (p = 0.139), but not at the 
decision point (p = <0.005). 
3.7.2.1.Noise sensitive group 
For the noise sensitive group (n = 14), there was a significant difference in the AWR between: 
baseline and week 1; baseline and week 11; baseline and decision point. There was a larger effect 
size at week 11 and decision point compared to week 1. The data are displayed in Table 5. 
Table 5 
Average weekly reaction score – noise sensitive group (n = 14) 
Week 
Noise sensitivities - Average weekly reaction score 
t-value 
(13) 
p-
value 
dCohen 
Mean +/− SD 
Decrease from baseline 
(95% CI) 
Median (range) 
Baseline 
21.11 +/− 
13.50 
- 
21.50 (4.92–
46.70) 
- - - 
1 
14.17 +/− 
11.65 
6.94 (3.07,10.81) 
10.50 (0.25–
34.00) 
3.87 0.002 −0.5504 
11 8.30 +/− 6.71 12.81 (6.55,19.08) 
7.00 (0.50–
26.50) 
4.42 0.001 −1.2017 
Decision 8.26 +/−11.11 12.85 (5.10,20.59) 
5.75 (0.00–
43.00) 
3.58 0.003 −1.039 
Non-social fear-anxiety group 
For the non-social fear-anxiety group (excluding noise sensitivities) (n = 8), there was a significant 
difference in the average weekly reaction scores between: baseline and week 1; baseline and week 
11; baseline and decision point. There was a larger effect size at week 11 and decision point 
compared to week 1. The data are displayed in Table 6. 
Table 6 
Average weekly reaction score – non-social fear/anxiety group (excluding noise sensitivities) (n = 8) 
Week 
Non-Social - Average weekly reaction score 
t-value 
(7) 
p-
value 
dCohen 
Mean +/− SD 
Decrease from baseline (95% 
CI) 
Median (range) 
Baseline 
18.57 +/− 
10.20 
- 
19.02 (1.79–
30.00) 
- - - 
1 9.76 +/− 6.59 8.81 (2.03,15.60) 
10.17 (0.00–
20.00) 
3.07 0.018 −0.782 
11 6.78 +/− 5.56 11.79 (6.07,17.51) 
7.88 (0.00–
15.00) 
4.88 0.002 −2.786 
Decision 6.51+/− 5.57 12.06 (4.75,19.38) 
6.88 (0.00–
15.00) 
3.90 0.006 −2.824 
Social fear-anxiety group 
For the social fear-anxiety group (n = 13), there was a significant difference in the average weekly 
reaction scores between: baseline and week 1; baseline and week 11; baseline and decision point. 
There was a larger effect size at week 11 and decision point compared to week 1. The data are 
displayed in Table 7. 
Table 7 
Average weekly reaction score – social fear/anxiety group (including single case of separation 
related problems) (n = 13) 
Week 
Social - Average weekly reaction score 
t-value 
(12) 
p-value dCohen Mean +/− 
SD 
Decrease from baseline 
(95% CI) 
Median (range) 
Baseline 
25.68 +/− 
7.82 
- 
27.20 (13.00–
38.00) 
- - - 
1 
15.48 +/− 
8.97 
10.20 (7.15,13.25) 
19.00 (1.33–
26.25) 
7.28 <0.001 −1.112 
11 
8.48 +/− 
6.11 
17.20 (12.81,21.59) 
7.00 (0.00–
17.00) 
8.54 <0.001 −2.451 
Decision 
8.22 +/− 
6.38 
17.46 (12.73,22.20) 7.00 (0.00–19.33 8.03 <0.001 −2.447 
These results indicate large effects in reducing average weekly reaction scores across dogs with 
noise sensitivities, social and non-social fears and anxieties, with significant effects being seen within 
the first week across all groups, and larger effects being seen at week 11 and decision points 
compared to week 1. 
Effects on temperament 
Negative activation 
The paired sample t-test used to compare negative activation scores showed a significant difference 
in the mean scores between baseline and the decision point with a large effect size. 
Positive activation 
There was no significant difference in the mean positive activation scores between baseline and the 
decision point. Effect size was therefore not calculated. The data are displayed in Table 8. 
Table 8 
Positive and negative activation scale scores 
Week 
Baseline  
Mean +/− 
SD 
Baseline  
Median 
(range) 
Decision 
Point  
Mean +/− 
SD 
Decision 
Point  
Median 
(range) 
Mean Decrease 
from  
baseline (95% 
CI) 
t-
value 
(16) 
p-
value 
dCohen 
Negative 
activation 
0.7541 
+/− 
0.1148 
0.78 
(0.51–
0.91) 
0.6053 
+/− 
0.1216 
0.58 
(0.42–
0.80) 
0.1488 
(0.0865,0.2111) 
5.07 <0.001 −1.258 
Positive 
activation 
0.6653 
+/− 
0.1152 
0.70 
(0.52–
0.84) 
0.6665 
+/− 
0.1236 
0.66 
(0.52–
0.87) 
0.0012 
(0.0303,0.0280) 
−0.09 0.933 - 
These results suggest that imepitoin alongside a behaviour modification programme has a large 
statistically significant effect on reducing negative activation (i.e. fearfulness/anxiousness in dogs) as 
measured through the PANAS. 
Owner satisfaction with treatment 
Owners were also asked to rate their overall satisfaction with treatment success: 6 (35.3%) were 
very satisfied, 6 (35.3%) satisfied, 4 (23.5%) partly satisfied/partly dissatisfied, 0 dissatisfied and 1 
(5.9%) very dissatisfied. The owner who was very dissatisfied (case 15) reported an improvement in 
anxiety on walks during treatment, but insufficient change in reactions to noises which was the main 
presenting problem. 
There was no correlation between owner satisfaction with either percentile reduction in average 
global weekly fear-anxiety reactions (rs = −0.288; p = 0.262) or percentile reduction in negative 
activation from baseline to decision point. (rs = −0.201; p = 0.439). 
Continuation of treatment at owners’ expense 
Of the 17 owners, 13 (76.5%) suggested they would use imepitoin at their own expense: 5 opted to 
use it on a continual basis from the end of the follow up period; 5 suggested they would consider 
using it on a tactical basis (e.g. leading up to and for the duration of periods during the year with 
increased risk of exposure to stressors); 3 suggested they would use it either continually or tactically 
depending on the outcome of discontinuing the imepitoin on their dog’s behaviour – i.e. if 
improvements seen during the treatment period were not sustained, they would consider restarting 
the use of imepitoin. The remaining 4 owners (23.5%) suggested they would not consider using 
imepitoin again. In 3 of the 5 cases who opted to stop imepitoin on a continual basis and consider 
use on a tactical basis, the consulting clinician (KM) would have preferred using the imepitoin on a 
continuous basis given the reported improvements during the follow up period. In all other decisions 
the clinician was in complete agreement with the client’s decision. 
Ease of administration 
At the end of the study, owners were asked to rate the ease of administration of imepitoin with the 
results  
being: 6 (35.3%) very easy, 9 (52.9%) easy, 2 (11.8%) moderately easy/moderately difficult. No 
owners rated administration as difficult or very difficult. 
Additional information 
Owner reported improvements with change in dose of imepitoin 
During the study, there were 7 owner reports of improvements in behaviour quickly following dose 
increases in imepitoin suggesting specific efficacy of imepitoin. Five cases where dose was increased 
from approximately 10 mg/kg to 20 mg/kg (Cases 5, 11, 12, 13, 16), and 2 cases where dose was 
increased from around 20 mg/kg to around 30 mg/kg (Cases 2, 12). 
Owner reported reduction in recovery time during treatment with imepitoin 
Three owners (Case 5, 12, 13) reported reduction in recovery time (i.e. quicker recovery) whilst on 
imepitoin following exposure to fireworks compared to previous years. 
Owner reported deterioration on cessation of imepitoin 
Two owners continued to keep diary entries through weaning, and behavioural deterioration on 
cessation of therapy with continuation of the behaviour modification programme suggests specific 
efficacy of imepitoin. In case 15 the owner reported an increase reluctance to go for walks which 
had improved during the period on imepitoin. In Case 3 the owner reported an increase in noise 
sensitivity and reactivity to other dogs at classes which had improved during the period on 
imepitoin. 
Dog’s responses from diaries 
A total of 1210 individual diary forms were completed by owners during the study. Dog’s responses 
for each of the options from the diary were assessed with mean scores between baseline (‘off 
imepitoin) and the entire treatment period (‘on imepitoin’) with the percentage change shown in 
Table 9. There was a reduction in mean scores of all clinical signs across all eliciting contexts during 
treatment compared with baseline with the exception of one single episode of diarrhoea (under title 
of ‘vomiting/urinating/defecating’) when home alone reported for Case 17 which was reported as an 
adverse event. 
Table 9 
Clinical signs as reported by owners across all eliciting contexts between baseline and whole period 
on imepitoin 
Dog’s response from  
eliciting context diary 
Mean scores  
at baseline 
Mean scores  
on imepitoin 
% change  
in scores 
Running around 0.802 0.412 −48.6 
Drooling saliva 0.481 0.165 −65.7 
Hiding 1.091 0.577 −47.1 
Destructiveness 0.092 0.017 −81.5 
Table 9 
Clinical signs as reported by owners across all eliciting contexts between baseline and whole period 
on imepitoin 
Dog’s response from  
eliciting context diary 
Mean scores  
at baseline 
Mean scores  
on imepitoin 
% change  
in scores 
Cowering 2.588 1.096 −57.7 
Restlessness/pacing 1.344 0.570 −57.6 
Aggressive behaviour 0.310 0.154 −50.3 
“Freezing” to the spot 1.114 0.459 −58.8 
Barking/whining/howling 0.786 0.608 −22.6 
Panting 1.605 0.772 −51.9 
Vomiting/defecating/ 
urinating 
0.000 0.005 +0.50 
Owner-seeking behaviour 1.277 0.750 −41.3 
Vigilance/scanning of  
environment 
2.128 1.406 −33.9 
Bolts 0.939 0.460 −51.0 
Exaggerated response  
when startled 
2.273 1.063 −53.2 
Shaking or trembling 1.567 0.482 −69.2 
Self-harm 0.017 0.007 −58.8 
Yawning 0.522 0.249 −52.3 
Licking lips 1.693 0.683 −59.7 
Moving away 1.661 0.477 −71.3 
Discussion 
These results provide initial evidence of the potential value of using imepitoin alongside a behaviour 
modification programme in reducing the average weekly global scores reported by owners of dogs 
with fear-anxiety  
related problems. When grouped into noise sensitivity, social and non-social fear-anxiety based 
problems, a reduction in average weekly reaction scores were seen across all groups. These effects 
appeared to be quick acting (within a week of the onset of administration of treatment) but improve 
over time. In addition imepitoin alongside a behaviour modification programme significantly 
reduced owner report of fearfulness as a temperament trait in dogs. Therefore it may be of value in 
cases where dogs have been identified as having a generally fearful or anxious temperament and 
potentially to help prevent a recurrence of problems in such individuals, although this remains to be 
tested empirically. At the end of the study 76.5% of owners would consider using imepitoin at their 
own expense, 88.2% of owners found imepitoin very easy or easy to administer, and 70.6% of 
owners were satisfied or very satisfied with treatment success. This demonstrates that there were 
also clinically meaningful improvements being seen by dog owners during the treatment period, 
although owner satisfaction did not relate to the scale of improvement measured here. This might 
be because owner satisfaction may depend on a few signs that are of particular concern to them 
(e.g. destructiveness or vocalisation) [10] whereas the metric used to assess improvement considers 
all signs even if not problematic to the owner. 
Although case series provide a relatively low level of evidence among clinical studies [45] they can 
serve an important purpose in advancing medical knowledge [46]; for example, this report provides 
the first exploration of the potential application of imepitoin as an anxiolytic for clinical behaviour 
problems. The majority of dogs had multiple problems extending from fear-anxiety, and so two 
types of metric were used. One type of metric (average global weekly scores; negative activation 
scores) gave a measure of the overall response for the totality of problems. The other (average 
weekly reaction scores) focused on the response to treatment to particular types of problem, 
grouped by context into social, non-social or noise related fear-anxiety problems. This resulted in 
dogs being included in multiple evaluations for average weekly reaction scores according to which 
context(s) the problem(s) were apparent, however only data relating to the relevant eliciting 
contexts for that context were included in that assessment, and not the global problem data. 
In the current study, baseline diary entries before commencing treatment meant each dog could 
acted as its own control, and although there was no control for dogs receiving imepitoin without 
behaviour modification advice, this is more typical of the recommended way of using medication in 
clinical behaviour cases. Medication is typically used as an adjunct to behaviour modification advice 
therefore this study replicates how imepitoin would likely be used in veterinary behavioural practice. 
However, given the rapid onset of effect within the first week, the finding that during the study 
there were 7 owner reports of improvements in behaviour quickly following dose increases, and the 
2 owner reports of deterioration in their dogs behaviour on cessation of imepitoin, it seems likely 
that there is a specific effect of the drug in these cases and the results are not simply due to the 
behaviour modification programme. 
These improvements seen within the first week of treatment, also raise the question of the potential 
to use imepitoin tactically. In the current study, this was important for those owners who saw 
benefits whilst their dog was on imepitoin but did not wish to use it continuously, but would 
consider using it at times of the year where there would be an increased risk of exposure to triggers 
for fear-anxiety (e.g. fireworks season, shooting season). For these cases it was advised to use 
imepitoin, in future, at the dose found to be effective during the current study, commencing 1 week 
before the anticipated onset of problematic triggers, and for the duration of this period (this could 
range from days to weeks depending on the trigger and level of exposure in the environment 
anticipated by the owner for the dog). Currently unlicensed benzodiazepines are often used 
tactically, given 30–60 min before the fear-anxiety trigger is expected, but responses to medication 
by individuals are often hard to predict [2425]. Further studies are required to investigate the 
potential benefits of using imepitoin in this way or in the context of individual dosing in relation to a 
specific event, in particular, the minimum period of time imepitoin can be given for an effect to be 
seen. Typically other anxiolytics such as SSRIs and TCAs may have an onset of action of around 3–
5 weeks [15], so in cases where a more rapid onset of action is required, imepitoin may be a valuable 
option. 
There were significant differences in reports of reactions to noises between week 1 of treatment and 
both week 11 and decision point. It should be noted that the average dosage of imepitoin being 
administered across all dogs differed at these time points, as it was determined and increased on an 
individual basis. Mean dos 
age at week 1 was 10.6 mg/kg, at week 11 was 17.7 mg/kg, and at the decision point was 
21.3 mg/kg. Reduction in reaction scores could therefore reflect a difference in dose being given, be 
the result of a longer duration of treatment or reflect the synergistic effect of imepitoin and 
behaviour modification therapy. However, in light of these findings 20 mg/kg imepitoin twice daily 
appears to be a reasonable recommended dose for anxiolytic effects with dose titration built around 
this dose according to effect. 
The study used a standardised diary format to reduce subjectivity in owner responding, and self-
reporting to gather data for analysis. There can be multiple limitations with this method - during the 
study there were 3 owners who suggested that they were failing to record all eliciting contexts 
resulting in ‘no response’ from their dog. This suggests that improvements may actually have been 
under-reported. The diary was used to record a summary of what the owner saw during the whole 
event their dog was exposed to the eliciting context, and there was no standardised duration of time 
each owner was required to observe their dog for. A caregiver placebo effect has been shown in 
dogs receiving treatment for osteoarthritis [47] and should also be considered when assessing the 
data from the study, which can potentially result in over-reporting of improvements by owners. The 
diary used did not include a section on recovery time after exposure to an eliciting context however 
3 owners spontaneously reported reduced recovery times after exposure to noises compared to the 
time before treatment with imepitoin. Recovery time might therefore be a useful metric to include 
in future studies. 
There were 6 dogs with 7 reported adverse events during the trial, with a high likelihood (as judged 
by the authors) of the imepitoin being implicated in 2 of these (mild ataxia, Case 11, Kai; diarrhoea, 
Case 17, Lexi) but the likelihood of the drug’s involvement in the other 3 is largely unknown although 
in one we consider it unlikely (Case 1). 
Paradoxical excitement can occur in species (including dogs) receiving benzodiazepines [2431], and 
although a potential adverse effect of using imepitoin is transient hyperactivity [35], there were no 
dogs in the study where this was reported. 
Tolerance to the effects of benzodiazepines can  
develop with ongoing use [1531] such as those  
demonstrated in anxiolytic models in mice [48]. The development of tolerance to the anticonvulsant 
effects of diazepam in dogs has also been documented [49]; however tolerance to the 
anticonvulsant effects of imepitoin has not been demonstrated [3337]. Additionally, when looking at 
anxiolysis, the results of this study showed significant effects within the first week of treatment with 
continued improvements seen at week 11 and decision points which is not suggestive of tolerance 
developing within this time frame. 
Concerns have been raised over the potential for benzodiazepines disinhibiting and therefore 
increasing aggressive behaviour in dogs and other species [1531] and one study reported increased 
aggressive behaviour and new aggression in a small proportion of dogs treated with diazepam [24]. 
There were no dogs in the study where aggressive behaviour was reported in the diary entries where 
it had not been seen before, and overall, there was a 50.3% reduction in owner reported signs of 
aggressive behaviour across all dogs whilst on imepitoin compared to the baseline period. 
In the human literature, there is conflicting evidence supporting or refuting the amnesic, memory 
and cognitive impairing effects of long term benzodiazepine use (for a meta-analysis and review see 
[50]). During the study there were no reports of adverse events suggestive of memory impairments 
such as loss of previously learned behaviours. In addition, all owners were asked to use operant 
and/or classical conditioning as part of their individualised behaviour modification programmes and 
subjectively there appeared to be no difficulty in implementation of such training protocols. 
It is important to consider both the physical health and concurrent medical problems of any patient 
presenting with a behavioural complaint [51]. Although this study excluded dogs with a history of 
seizures, given that behavioural co-morbidities are common in canine epilepsy [38], further studies 
could explore the value of using imepitoin in these patients. Musculoskeletal pain may cause or 
exacerbate behaviour problems such as aggressive behaviour [5253]. Fear and anxiety may also 
amplify pain [54]. For these reasons, it was important to establish that any medical abnormalities 
detected on clinical examination were investigated and treated prior to commencing imepitoin and a 
behaviour modification plan, which occurred in 6 of the 20 dogs enrolled in the study. Indeed 11 
subjects were not enrolled in the study due to uncontrolled medical reasons, with 8 of these related 
to suspected musculoskeletal pain. In addition one dog (Case 1) was withdrawn from the analysis 
due to recurring lameness which resulted in increased general anxiety and required a change in 
analgesia. Pain remains an important differential and moderator of response in anxiety cases, and so 
all cases need careful medical evaluation. 
Conclusions 
This report provides the first exploration of the potential application of imepitoin as an anxiolytic for 
clinical behaviour problems. This study suggests that imepitoin may be an effective medication to aid 
the treatment of a range of fear-anxiety based problems when used alongside a behaviour 
modification programme. The current veterinary formulation of imepitoin licensed for long term use 
in dogs with epilepsy appears to be safe and well tolerated. A dose of 20 mg/kg imepitoin twice daily 
appears to be an appropriate starting dose for anxiolytic effects in most patients, with a fast onset of 
action with improvements being seen within the first week of commencing treatment, giving it an 
advantage over some other classes of anti-anxiety medication such as TCAs and SSRIs. Further 
research with a randomized, double-blind, placebo-controlled trial would be useful to confirm the 
apparent efficacy reported here. 
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